S&P Futures
3,860.00 +11.75 (+0.31%) Dow Futures
31,104.00 +91.00 (+0.29%) Nasdaq Futures
11,927.00 +46.75 (+0.39%) Russell 2000 Futures
1,735.70 +7.10 (+0.41%) Crude Oil
98.81 +0.28 (+0.28%) Gold
1,744.20 +7.70 (+0.44%)
Verastem, Inc. (VSTM)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.2200 |
| Open | 1.2200 |
| Bid | 0.0000 x 1100 |
| Ask | 0.0000 x 4000 |
| Day's Range | 1.1700 - 1.2322 |
| 52 Week Range | 1.0000 - 3.8200 |
| Volume | |
| Avg. Volume | 2,539,260 |
| Market Cap | 219.906M |
| Beta (5Y Monthly) | 0.89 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4110 |
| Earnings Date | Aug 01, 2022 - Aug 05, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.25 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for VSTM
Related Research
- Verastem, Inc.Technical Assessment: Bearish in the Intermediate-TermCommodities continue to get shellacked, Treasury yields across the curve are still falling, people are starting to suggest that the Federal Reserve won't have to tighten as much as many thought just a month or two ago, recession fears (or worries that we are already in one) are rising quickly, EPS season is almost upon us (with many believing 2022 numbers are far too high), crypto remains in the dumpster, and the horrendous invasion of Ukraine never ends.RatingFair ValueEconomic Moat23 hours agoArgus Research
- Simply Wall St.
What You Need To Know About Verastem, Inc.'s (NASDAQ:VSTM) Investor Composition
The big shareholder groups in Verastem, Inc. ( NASDAQ:VSTM ) have power over the company. Institutions often own shares...
- Benzinga
RBC Says Verastem Interim Analysis In Ovarian Cancer Reinforces Enthusiasm
With the anticipation of a 2Q program update, Verastem Oncology (NASDAQ: VSTM) announced that its interim analysis findings for the RAMP 201 program for recurrent low-grade serous ovarian cancer (LGSOC) continue evaluation in both monotherapy and combination regimens. With incremental updates from ASCO, reiterated KOL enthusiasm, and more updates are upcoming in 2022 on a longer runway, RBC Capital continues to like the VSTM setup. The company plans to complete enrollment of all four trial cohor
- Business Wire
Verastem Oncology Provides Update on RAMP 201 Study Evaluating VS-6766 ± Defactinib in Low-Grade Serous Ovarian Cancer
BOSTON, June 06, 2022--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for people living with cancer, today announced an update from an interim analysis of its international Phase 2 RAMP 201 trial evaluating VS-6766 ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC), regardless of KRAS status.
